Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

miRNA and Myokines in Patients With PAH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03905083
Recruitment Status : Recruiting
First Posted : April 5, 2019
Last Update Posted : April 5, 2019
Sponsor:
Information provided by (Responsible Party):
Michael Risbano, University of Pittsburgh

Brief Summary:

The overall objective of this study is to fulfill the Pilot study (miRNA and Myokines Acutely-expressed During Exercise) goal to Investigate the excretion of skeletal muscle-derived miRNA and myokines in patients with pulmonary arterial hypertension during acute exercise that are biologically active and modulate skeletal muscle function during exercise.

Pulmonary arterial hypertension (PAH), is characterized by the proliferation of endothelial and smooth muscle cells within the precapillary pulmonary vasculature, if untreated results in increased pulmonary vascular resistance and death. The hallmark perivascular infiltrates in PAH contain inflammatory macrophages and lymphocytes resulting in endothelial dysfunction and involves the dysregulation of distinct inflammatory mechanisms. Idiopathic PAH (iPAH) and scleroderma-associated PAH (SSc-PAH), are related by similar clinical and pathophysiologic features. Patients with PAH experience a central cardiovascular limitation to exercise. Despite effective treatment with pulmonary vasodilators, many resting PAH (rPAH) patients continue to experience exercise intolerance. PAH is increasingly acknowledged as a systemic disease, beyond abnormalities of the pulmonary vasculature. Although other contributions to exercise intolerance in PAH exist, skeletal muscle dysfunction significantly impacts exercise tolerance. The molecular mechanisms behind skeletal muscle dysfunction in PAH remain unclear. Provocative testing with invasive cardiopulmonary exercise testing challenges the cardio-pulmonary-vascular and skeletal muscle systems and elicits a cascade of physiologic events not measurable at rest. Myokines are circulating mediators released from skeletal muscle in an endocrine-like fashion in disease and health influencing many factors but not limited to systemic inflammation, immunity and endothelial function. Myokines have not been well described in PAH. Preliminary data indicate that myokines play important, yet still undescribed, roles in this disease. MicroRNAs (miRNAs) are small non-coding RNA molecules, which negatively regulate gene expression via repressing translation and degrading messenger RNAs through sequence-specific binding. There is a growing literature regarding the biological activity of extracellular miRNAs in PAH and in aerobic exercise. miR-126 has been implicated in skeletal muscle dysfunction in PAH, while miR-133 is skeletal muscle-specific but unlike miR-126 it is not yet implicated in skeletal muscle dysfunction in PAH.


Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Other: Exercise Rehab Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: miRNA and Myokines Acutely-expressed During Exercise in Patients With Pulmonary Arterial Hypertension
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : March 15, 2020
Estimated Study Completion Date : June 15, 2020


Arm Intervention/treatment
Experimental: Exercise rehab
Investigators aim to evaluate how exercise training may provide beneficial effects on the skeletal muscle and/or pulmonary vasculature in select subjects with pulmonary arterial hypertension, scleroderma or mixed connective tissue disease or patients with exercise pulmonary arterial hypertension
Other: Exercise Rehab
Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.

No Intervention: No exercsie rehab
Some participants will not be assigned to do exercise rehab so we would be using them as a control arm to intervention group



Primary Outcome Measures :
  1. To evaluate the impact of released miRNA/myokines on the skeletal muscle in PAH patients. [ Time Frame: At the time of the procedure ]
    We will be able to measure the levels of miRNA by doing RNA sequencing and then To evaluate the impact of released miRNA/myokines on the skeletal muscle in PAH patients.Protein and transcript levels will be confirmed using Western blots and real-time PCR

  2. To evaluate the impact of formal exercise training on the skeletal muscle [ Time Frame: At the time of the procedure ]

    Muscle biopsy for miRNA and myokine assessment will be performed for this outcome. Total RNA and protein extracted from quadriceps muscle biopsies will be used to measure RNA and protein expression. We will perform a secretome analysis utilizing the Mass Spectrometry Lab at the University of Pittsburgh for an unbiased assessment of muscle-secreted myokines in our subjects.

    RNA sequencing and then Protein and transcript levels will be confirmed using Western blots and real-time PCR


  3. To evaluate the impact of formal exercise training on the pulmonary vasculature system [ Time Frame: At the time of the procedure ]
    This will be done by measuring hemodynamics during invasive cardiopulmonary exercise test. We will correlate miRNA and myokines released from the skeletal muscle with measures of oxygen delivery and extraction in the muscle and oxygen consumption - calculated from arterial and pulmonary artery blood gasses and invasive hemodynamics. Oxygen delivery to peripheral tissues is determined by (Q ) ̇x CaO2. Oxygen extraction is Ca-vO2. Oxygen consumption is continuously measured by iCPET as( V) ̇O2. Systemic oxygen extraction ratio is determined by (Ca-vO2)/ CaO2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing a RHC/iCPET procedure at the UPMC Presbyterian Hospital Catheterization Lab.
  • 18 years of age or older
  • Able to read and understand the informed consent.
  • Subjects who have signed the iCPET registry consent.

Exclusion Criteria:

  • Pregnant women
  • people under 18
  • Who are unable to read and understand the informed consent.
  • Subjects prescribed anticoagulant therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03905083


Contacts
Layout table for location contacts
Contact: Yassmin Al Aaraj, MD 4126479227 alaarajyy@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
Division of Pulmonary, Allergy and Critical Care Medicine Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Michael Risbano, MD    412-692-2210    risbanomg@upmc.edu   
Sponsors and Collaborators
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: Michael Risbano, MD University of Pittsburgh

Layout table for additonal information
Responsible Party: Michael Risbano, Head, Clinical Operations for Pulmonary Hypertension, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03905083     History of Changes
Other Study ID Numbers: PRO18110141
First Posted: April 5, 2019    Key Record Dates
Last Update Posted: April 5, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Our IPD plan would include:

  1. The use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access through asking data requester to fill up formal application that would give details on how this data would be used.
  2. Seeking consent for sharing IPD from the clinical trial participants with adequate assurance that patient privacy and confidentiality can be maintained.
  3. Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organizations and users of IPD.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases